Atlas Trials

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Clinical trial NCT02401048 · COMPLETED

Trial details

NCT number
NCT02401048
Sponsor
Pharmacyclics LLC.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Diffuse Large B-Cell LymphomaFollicular Lymphoma
Start date
2015-05-01
Primary completion
2017-11-01
Enrollment
61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.